Bryan Iorgulescu, MD, MPH, FCAP
Department of Hematopathology, Division of Pathology-Lab Medicine Div
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Hematopathology (Molecular Diagnostics Laboratory), Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston
Education & Training
Degree-Granting Education
| 2022 | Harvard School of Public Health, Boston, MPH, Clinical Effectiveness |
| 2015 | Weill Cornell Medical College of Cornell University, New York, MD, Medicine |
Postgraduate Training
| 2022-2023 | Clinical Fellowship, Molecular Genetic Pathology, UT MD Anderson Cancer Center, Houston |
| 2018-2022 | Research Fellowship, Cancer Genomics and Immuno-oncology, Dana-Farber Cancer Institute/Harvard Medical School/Broad Institute, Boston |
| 2015-2018 | Clinical Residency, Anatomic Pathology, Brigham and Women's Hospital, Boston |
Board Certifications
| 2023 | American Board of Pathology (Molecular Genetic Pathology) |
| 2018 | American Board of Pathology (Anatomic Pathology) |
Experience & Service
Academic Appointments
Instructor, Department of Pathology, Havard Medical School & Brigham and Women's Hospital, Boston, 2020 - 2022
Honors & Awards
| 2022 - 2023 | ASCO Journals Editorial Fellowship, American Society of Clinical Oncology |
| 2021 | 2nd Runner Up, Clinical Scientist Award, Immuno-Oncology Young Investigators’ Forum |
| 2020 | Conquer Cancer/ASCO Meeting Merit Award, American Society of Clinical Oncology |
| 2020 | Abstract Travel Award, Society for Immunotherapy of Cancer |
| 2020 | Abstract Poster Award, Society for Neuro-Oncology |
| 2020 | Scholar-in-Training Award, AACR Cancer Health Disparities Conference |
| 2020 - 2022 | Young Investigator Award, Conquer Cancer Foundation/ASCO/Sontag Foundation |
| 2020 - 2022 | K12 Paul Calabresi Career Development Award, NCI, Massachusetts General Hospital |
| 2018 | Richard Davis Travel Award, American Association of Neuropathologists |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Lim-Fat MJ, Iorgulescu JB, Rahman R, Bhave V, Muzikansky A, Woodward E, Whorral S, Allen M, Touat M, Li X, Xy G, Patel J, Gerstner ER, Kalpathy-Cramer J, Youssef G, Chukwueke U, McFaline-Figueroa JR, Nayak L, Lee EQ, Reardon DA, Beroukhim R, Huang RY, Bi WL, Ligon KL, Wen PY. Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma. Clin Cancer Res 30(7):1327-1337, 2024. PMID: 38252427.
- Iorgulescu JB, Medeiros LJ, Patel KP. Predictive and prognostic molecular biomarkers in lymphomas. Pathology 56(2):239-258, 2024. e-Pub 2023. PMID: 38216400.
- Subbiah V, Gouda MA, Iorgulescu JB, Dadu R, Patel K, Sherman S, Cabanillas M, Hu M, Castellanos LE, Amini B, Meric-Bernstam F, Shen T, Wu J. Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ Precis Oncol 8(1):62, 2024. e-Pub 2024. PMID: 38438731.
- Russell AJC, Weir JA, Nadaf NM, Shabet M, Kumar V, Kambhampati S, Raichur R, Marrero GJ, Liu S, Balderrama KS, Vanderburg CR, Shanmugam V, Tian L, Iorgulescu JB, Yoon CH, Wu CJ, Macosko EZ, Chen F. Slide-tags enables single-nucleus barcoding for multimodal spatial genomics. Nature 625(7993):101-109, 2024. e-Pub 2023. PMID: 38093010.
- Chong SJF, Zhu F, Dashevsky O, Mizuno R, Lai JX, Hackett L, Ryan CE, Collins MC, Iorgulescu JB, Guièze R, Penailillo J, Carrasco R, Hwang YC, Muñoz DP, Bouhaddou M, Lim YC, Wu CJ, Allan JN, Furman RR, Goh BC, Pervaiz S, Coppé JP, Mitsiades CS, Davids MS. Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies. J Clin Invest. e-Pub 2023. PMID: 37751299.
- Ostrom QT, Shoaf ML, Cioffi G, Waite K, Kruchko C, Wen PY, Brat DJ, Barnholtz-Sloan JS, Iorgulescu JB. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. Neuro Oncol 25(4):799-807, 2023. PMID: 35994777.
- Gutierrez C, Ogino S, Meyerhardt JA, Iorgulescu JB. The Prevalence and Prognosis of Microsatellite Instability-High/Mismatch Repair-Deficient Colorectal Adenocarcinomas in the United States. JCO Precis Oncol 7:e2200179, 2023. PMID: 36716414.
- Iorgulescu JB, Sun C, Neff C, Cioffi G, Gutierrez C, Kruchko C, Ruhl J, Waite KA, Negoita S, Hofferkamp J, Tihan T, McLendon R, Brat DJ, Ostrom QT, Barnholtz-Sloan JS. Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. Neuro Oncol 24(11):1989-2000, 2022. PMID: 35460555.
- Liu S, Iorgulescu JB, Li S, Borji M, Barrera-Lopez IA, Shanmugam V, Lyu H, Morriss JW, Garcia ZN, Murray E, Reardon DA, Yoon CH, Braun DA, Livak KJ, Wu CJ, Chen F. Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response. Immunity 55(10):1940-1952.e5, 2022. PMID: 36223726.
- Papke DJ, Lindeman NI, Schrag D, Iorgulescu JB. Underutilization of Guideline-Recommended Mismatch Repair/Microsatellite Instability Biomarker Testing in Advanced Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 31(9):1746-1751, 2022. PMID: 35767976.
- Lamba N, Ott PA, Iorgulescu JB. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era. JAMA Netw Open 5(8):e2225459, 2022. e-Pub 2022. PMID: 36006646.
- Oliveira G, Stromhaug K, Cieri N, Iorgulescu JB, Klaeger S, Wolff JO, Rachimi S, Chea V, Krause K, Freeman SS, Zhang W, Li S, Braun DA, Neuberg D, Carr SA, Livak KJ, Frederick DT, Fritsch EF, Wind-Rotolo M, Hacohen N, Sade-Feldman M, Yoon CH, Keskin DB, Ott PA, Rodig SJ, Boland GM, Wu CJ. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature 605(7910):532-538, 2022. e-Pub 2022. PMID: 35508657.
- Gohil SH, Iorgulescu JB, Braun DA, Keskin DB, Livak KJ. Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. Nat Rev Clin Oncol 18(4):244-256, 2021. e-Pub 2020. PMID: 33277626.
- Hu Z, Leet DE, Allesøe RL, Oliveira G, Li S, Luoma AM, Liu J, Forman J, Huang T, Iorgulescu JB, Holden R, Sarkizova S, Gohil SH, Redd RA, Sun J, Elagina L, Giobbie-Hurder A, Zhang W, Peter L, Ciantra Z, Rodig S, Olive O, Shetty K, Pyrdol J, Uduman M, Lee PC, Bachireddy P, Buchbinder EI, Yoon CH, Neuberg D, Pentelute BL, Hacohen N, Livak KJ, Shukla SA, Olsen LR, Barouch DH, Wucherpfennig KW, Fritsch EF, Keskin DB, Wu CJ, Ott PA. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med 27(3):515-525, 2021. e-Pub 2021. PMID: 33479501.
- Iorgulescu JB, Gokhale PC, Speranza MC, Eschle BK, Poitras MJ, Wilkens MK, Soroko KM, Chhoeu C, Knott A, Gao Y, Lim-Fat MJ, Baker GJ, Bonal DM, Nguyen QD, Grant GRL, Ligon KL, Sorger PK, Chiocca EA, Anderson AC, Kirschmeier PT, Sharpe AH, Freeman GJ, Reardon DA. Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clin Cancer Res 27(1):276-287, 2021. e-Pub 2020. PMID: 33239433.
- Lamba N, Chukwueke UN, Smith TR, Ligon KL, Aizer A, Reardon DA, Iorgulescu JB. Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma. JAMA Oncol 6(12):1972-1974, 2020. PMID: 33090181.
- Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, Cortes-Ciriano I, Birzu C, Geduldig JE, Pelton K, Lim-Fat MJ, Pal S, Ferrer-Luna R, Ramkissoon SH, Dubois F, Bellamy C, Currimjee N, Bonardi J, Qian K, Ho P, Malinowski S, Taquet L, Jones RE, Shetty A, Chow KH, Sharaf R, Pavlick D, Albacker LA, Younan N, Baldini C, Verreault M, Giry M, Guillerm E, Ammari S, Beuvon F, Mokhtari K, Alentorn A, Dehais C, Houillier C, Laigle-Donadey F, Psimaras D, Lee EQ, Nayak L, McFaline-Figueroa JR, Carpentier A, Cornu P, Capelle L, Mathon B, Barnholtz-Sloan JS, Chakravarti A, Bi WL, Chiocca EA, Fehnel KP, Alexandrescu S, Chi SN, Haas-Kogan D, Batchelor TT, Frampton GM, Alexander BM, Huang RY, Ligon AH, Coulet F, Delattre JY, Hoang-Xuan K, Meredith DM, Santagata S, Duval A, Sanson M, Cherniack AD, Wen PY, Reardon DA, Marabelle A, Park PJ, Idbaih A, Beroukhim R, Bandopadhayay P, Bielle F, Ligon KL. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580(7804):517-523, 2020. e-Pub 2020. PMID: 32322066.
- Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS, Biran A, Fernandes SM, Brown JR, Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG, Neuberg D, Harper JW, Carr SA, Piccioni F, Ott CJ, Leshchiner I, Johannessen CM, Doench J, Mootha VK, Getz G, Wu CJ. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell 36(4):369-384.e13, 2019. e-Pub 2019. PMID: 31543463.
- Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, Le PM, Allesøe RL, Richman AR, Kowalczyk MS, Abdelrahman S, Geduldig JE, Charbonneau S, Pelton K, Iorgulescu JB, Elagina L, Zhang W, Olive O, McCluskey C, Olsen LR, Stevens J, Lane WJ, Salazar AM, Daley H, Wen PY, Chiocca EA, Harden M, Lennon NJ, Gabriel S, Getz G, Lander ES, Regev A, Ritz J, Neuberg D, Rodig SJ, Ligon KL, Suvà ML, Wucherpfennig KW, Hacohen N, Fritsch EF, Livak KJ, Ott PA, Wu CJ, Reardon DA. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565(7738):234-239, 2019. e-Pub 2018. PMID: 30568305.
- Iorgulescu JB, Freedman RA, Lester SC, Mittendorf EA, Brock JE. 21-Gene Recurrence Score Adds Significant Value for Grade 3 Breast Cancers: Results From a National Cohort. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32457931.
- Iorgulescu JB, Harary M, Zogg CK, Ligon KL, Reardon DA, Hodi FS, Aizer AA, Smith TR. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunol Res 6(9):1039-1045, 2018. e-Pub 2018. PMID: 30002157.
- Iorgulescu JB, Van Ziffle J, Stevers M, Grenert JP, Bastian BC, Chavez L, Stichel D, Buchhalter I, Samuel D, Nicolaides T, Banerjee A, Mueller S, Gupta N, Tihan T, Bollen AW, Northcott PA, Kool M, Pfister S, Korshunov A, Perry A, Solomon DA. Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. Acta Neuropathol 135(4):635-638, 2018. e-Pub 2018. PMID: 29435664.
Letters to the Editor
- Iorgulescu JB. Reporting of Immunotherapy and Biologic Therapy in the National Cancer Database. JAMA Oncol 9: 1003, 2023.
Patient Reviews
CV information above last modified May 12, 2024